期刊文献+

不同起源神经母细胞瘤N-myc基因扩增情况研究 被引量:1

A Study of the status of N-myc amplification in neuroblastoma originating from different sites
下载PDF
导出
摘要 目的了解不同类型神经母细胞瘤的生物学特性。方法在本研究中,对新诊断神经母细胞瘤患者的生物学特点(N-myc基因扩增)与临床特点进行了比较。结果共49例神经母细胞瘤,起源于腹膜后35例,其他14例。两个组呈现出不同的N-myc基因扩增情况(P<0.05)。结论不同临床类型的神经母细胞瘤存在有不同的生物学特性发布情况。 Objective To investigate the biological characteristics of neuroblastomas originating from different sites. Methods Fluorescent in situ hybridization (FISH) was employed to detect the status of N-myc amplification in patients with newly diagnosed neuroblastoma originating from different sites from July 2011 to June 2013. Results A total of 49 cases of pa- tients with newly diagnosed neuroblastoma were identified in the study, 35 cases of neuroblastoma originating from retroperitoneal site, 14 cases from other primary sites. There were significant differences in the N-myc amplification between the two groups (P 〈 0. 05 ). Conclusion Patients with neuroblastomas originating from extra-retroperitoneal sites might show a more favorable biological characteristics than from retroperitoneal site.
出处 《广州医药》 2015年第3期16-18,共3页 Guangzhou Medical Journal
关键词 神经母细胞瘤 N—myc基因扩增 腹膜后 Neuroblastoma N-myc amplification Retroperitoneal
  • 相关文献

参考文献14

  • 1Maris JM, Hogarty MD, Bagatell R, et al. Neuroblasto- ma [J]. Lancet, 2007, 369 (9579):2106-2120.
  • 2郑兆俭.神经母细胞瘤6例报告[J].哈尔滨医药,1990,10(1):27-29. 被引量:1
  • 3Liu YL, Miser JS, Hsu WM. Risk-directed therapy and research in neuroblastoma [ J]. J Formos Med Assoc, 2014, 113 (12): 887-889.
  • 4Shimada H, Ambros IM, Dehner LP, et al. The Inter- national Neuroblastoma Pathology Classification (the Shi- mada system) [J]. Cancer, 1999, 86 (2): 364-372.
  • 5Joshi VV, Cantor AB, Brodeur GM, et al. Correlation between morphologic and other prognostic markers of neu- roblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in pa- tients in the Pediatric Oncology Group [ J ]. Cancer 1993, 71 (10): 3173-3181.
  • 6Pession A, Tonelli R. The mycn oncogene as a specific and selective drug target for peripheral and central nerv- ous system tumors [ J ]. Curr Cancer Drug Targets, 2005, 5 (4): 273-283.
  • 7Hossain MM, Banik NL, Ray SK. N-Myc knockdown and apigenin treatment controlled growth of malignant neuro- blastoma cells having N-Mye amplification [ J ]. Gene, 2013, 529 (1): 27-36.
  • 8Zhang Z, Yu H, Huang J, et al. The TRPM6 kinase do- main determines the Mg^+ ATP sensitivity of TRPM7/M6 heteromeric ion channels [ J]. J Biol Chem, 2014, 289 (8) : 5217-5227.
  • 9Suita S, Tajiri T, Sera Y, et al. The characteristics of mediastinal neuroblastoma [J ]. Eur J Pediatr Surg, 2000, 10 (6): 353-359.
  • 10Calafiore L, Amoroso L, Della Casa Alberighi O, et al. Two-stage phase Ⅱ study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma [ J ]. Ann On- col, 2013, 24 (5): 1406-1413.

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部